drugset / Trial / NCT00265473
MGA031, Sirolimus and Tacrolimus in Islet Transplantation
Phase 1/2
Completed
5 enrolled
University of Minnesota
Juvenile Diabetes Research Foundation · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is designed to extend the observations made in our pilot clinical trial (IND 8971, Study #1) on the safety and efficacy of immunotherapy with the anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala), (currently called MGA031) combined with sirolimus and tacrolimus in preventing rejection and autoimmune destruction of deceased donor pancreatic islet transplants in type 1 diabetic recipients.
Timeline
- Start
- 2005-11
- Primary completion
- 2010-05
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic Islets of Langerhans | Cell therapy | — | Other |